Raludotatug deruxtecan Clinical Trials

2 actively recruiting trials across 2 locations

No change since June 2026

Also known as: DS-6000a, MK-5909, MK-5909, R-DXd, R-DXd

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

Merck Sharp & Dohme LLC2

Indications

Cancer2
Ovarian Cancer Recurrent1
Carcinoma, Non-Small-Cell Lung1
Lung Cancer1

New Haven, Connecticut1 trial

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)

Phase 1/2

Lexington, Kentucky1 trial

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

University of Kentucky Chandler Medical Center ( Site 0019)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.